Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles

BACKGROUND: Trans-acting programmed death-ligand 1 (PD-L1) derives from malignant cells in three known forms. High levels of secreted splice variant PD-L1 (sPD-L1), ADAM10/ADAM17-shed sPD-L1, and PD-L1-positive extracellular vesicles (evPD-L1) each predict poor prognosis and limited response to PD-(...

Descripción completa

Detalles Bibliográficos
Autores principales: Orme, Jacob J, Enninga, Elizabeth Ann L, Lucien-Matteoni, Fabrice, Dale, Heather, Burgstaler, Edwin, Harrington, Susan M, Ball, Matthew K, Mansfield, Aaron S, Park, Sean S, Block, Mathew S, Markovic, Svetomir N, Yan, Yiyi, Dong, Haidong, Dronca, Roxana S, Winters, Jeffrey L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437945/
https://www.ncbi.nlm.nih.gov/pubmed/32817395
http://dx.doi.org/10.1136/jitc-2020-001113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437945/
https://www.ncbi.nlm.nih.gov/pubmed/32817395
http://dx.doi.org/10.1136/jitc-2020-001113

Ejemplares similares